Current Headlines

  1. Charles River And The Francis Crick Institute Combine Expertise In Antibody-Drug Conjugate Development 10/22/2025

    Charles River Laboratories International, Inc. and The Francis Crick Institute (Crick) today announced a new collaboration around Antibody-Drug Conjugate (ADC) drug discovery and development, leveraging combined strengths to accelerate the development and delivery of next-generation targeted therapies.

  2. Syngene International Announces Plans To Add Bioconjugation Suite For End-To-End Antibody-Drug Conjugates Development 10/22/2025

    Syngene International, a global contract research, development and manufacturing organization (CRDMO), is adding a GMP bioconjugation suite at its commercial biologics facility [Unit 3] in Bengaluru.

  3. 7th Inflammasome Therapeutics Summit 10/21/2025

    Now in its 7th year, the Inflammasome Therapeutics Summit is the only industry forum focused exclusively on inflammasome-targeted drug development. Over three action-packed days, we will unpack high-impact case studies from the front lines – covering emerging upstream and downstream targets, mechanisms beyond canonical pathways, and how these insights are unlocking new disease areas from neuroinflammation and atopic dermatitis to obesity and fibrotic conditions.

  4. Quoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation For QRX003 In Netherton Syndrome 10/21/2025

    Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead product candidate, QRX003, for the treatment of Netherton Syndrome.

  5. Nxera's Partner Cancer Research UK Presents Data From Successfully Completed Phase 1 Clinical Trial Of Cancer Immunotherapy Drug HTL0039732 At ESMO 10/21/2025

    Nxera Pharma (“the Company” or “Nxera”;) announces that its partner, Cancer Research UK, presented data from the successfully completed Phase 1 part of the ongoing Phase 1/2a clinical trial (NCT05944237) of Nxera’s immunotherapy drug HTL0039732 (also known as NXE0039732) at the European Society for Medical Oncology Congress (ESMO) 2025 being held 17-21 October 2025 in Berlin, Germany.

  6. Topcon Healthcare Launches IDHea, Inc. To Advance Drug Development And Oculomics 10/21/2025

    Topcon Healthcare, Inc. officially launches IDHea, Inc., the Institute for Digital Health, a new company dedicated to transforming clinical research in eye care and oculomics.

  7. Dewpoint Therapeutics Announces An Open IND For First-In-Class Condensate Modulator DPTX3186 For Wnt-Driven Cancers 10/21/2025

    Dewpoint Therapeutics today announced the opening of an Investigational New Drug (IND) application to the U.S.

  8. Ventus Therapeutics Enters Into A Collaboration And License Agreement With Genentech To Discover And Develop Small-Molecule Medicines Using Ventus' ReSOLVE Platform 10/21/2025

    Ventus Therapeutics, a clinical-stage biopharmaceutical company advancing two Phase 2 small-molecule programs for immunological, inflammatory, and neurological disorders, today announced a multi-year collaboration with Genentech, a member of the Roche Group, to discover and optimize novel small-molecule candidates for challenging targets in major disease areas using Ventus’ proprietary drug discovery platform, ReSOLVE.

  9. Samsung Bioepis And Phrontline Announce A Global Strategic Partnership To Advance Best-In-Class Antibody-Drug Conjugate Therapeutics For Solid Tumors 10/20/2025

    Samsung Bioepis Co., Ltd. and Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), today announced that the companies have entered into a global collaboration agreement to develop, manufacture and commercialize two ADC assets: TJ108, bispecific and dual-payload ADC, and another asset to be named.

  10. Charles River And X-Chem Announce Strategic Collaboration To Enhance Hit Identification Capabilities 10/20/2025

    Charles River Laboratories International, Inc. today announced a strategic collaboration with X-Chem, Inc., the pioneer in DNA-encoded library (DEL) technology and a data-driven drug discovery company, to enhance its hit identification (Hit ID) capabilities and accelerate the discovery of novel therapeutics.